2009
Off-label use of approved drugs
DeVita V. Off-label use of approved drugs. Nature Reviews Clinical Oncology 2009, 6: 181-181. PMID: 19333219, DOI: 10.1038/nrclinonc.2009.41.Peer-Reviewed Original Research
1991
Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review?
DeVita V. Is a mechanism such as the NCI's Clinical Alert ever an appropriate alternative to journal peer review? Important Advances In Oncology 1991, 241-54. PMID: 1869279.Peer-Reviewed Original ResearchConceptsJournal peer review systemTraditional peer reviewJournal peer reviewNational research enterpriseClinical alertsPeer review systemNational Cancer Advisory BoardPeer reviewPublication of scientific worksCommunicating informationReview systemAcademic toolsAlertsPracticing physiciansAdvisory boardPhysiciansDecision-making processInformationColon cancerClinicStages of colon cancerResearch enterpriseAcademic advancementAdjuvant drug therapy
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answerErythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
Whang-Peng J, Lees D, Schuette W, Smith R, Bull J, DeVita V. Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy. Journal Of The National Cancer Institute 1981, 65: 1103-4. PMID: 7296555.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultColonic NeoplasmsDoxorubicinFemaleHot TemperatureHumansMaleMelanomaMiddle AgedNeoplasmsOsmotic FragilitySemustine
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchMeSH KeywordsColonic NeoplasmsDrug Administration ScheduleDrug EvaluationFemaleFluorouracilHumansInjections, IntraperitonealOvarian NeoplasmsConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levelsAdvances in the multimodal primary management of cancer.
DeVita V, Henney J, Weiss R. Advances in the multimodal primary management of cancer. Advances In Internal Medicine 1980, 26: 115-29. PMID: 7013437.Peer-Reviewed Original Research
1979
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancerThe dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Weiss R, DeVita V. The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon. Journal Of The American College Of Surgeons 1979, 149: 267-71. PMID: 380029.Peer-Reviewed Original Research
1975
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRisk